 |
| Plasma Protease C1-Inhibitor Treatment Market |
Plasma protease C1-inhibitor treatment is used for patients with hereditary angioedema (HAE), a rare genetic condition that causes frequent and painful episodes of swelling in various body parts including hands, feet, arms, legs, abdominal area, face, and airway. C1-inhibitor treatment can prevent and treat acute HAE attacks by inhibiting C1 activation and modulating the complement, contact, and fibrinolytic systems.
The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a 6.7% CAGR over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The increasing prevalence of hereditary angioedema (HAE) offers attractive growth opportunities for the plasma protease C1-inhibitor treatment market. HAE affects about 1 in 50,000 people worldwide with women twice as likely as men to have HAE. As there is no cure for HAE currently, the lifelong treatment of patients offers continuous sales potential for plasma protease C1-inhibitor treatment products. Moreover, the ongoing R&D for developing new treatments offering higher efficacy and convenience can further drive the adoption of plasma protease C1-inhibitor treatment among HAE patients over the forecast period.
Porter’s Analysis
Threat of new entrants: The plasma protease C1-inhibitor treatment market requires substantial R&D investments and regulatory approvals, creating high barriers to entry. However, large molecules generics pose a moderate threat once main patents expire.
Bargaining power of buyers: Individual buyers have low bargaining power due to inelastic demand and need for specialized treatment. However, large government and private insurance agencies wield significant influence over pricing.
Bargaining power of suppliers: A few global players control the supply chain for plasma fractionation and biological drug development. This concentrates supplier power despite high manufacturing costs.
Threat of new substitutes: Currently, there are no cost-effective substitutes for plasma-derived C1-inhibitor therapy in treating hereditary angioedema. However, monoclonal antibody drugs may emerge as alternatives.
Competitive rivalry: Competition is intense between leading manufacturers. They compete based on brand recognition, product efficacy, geographic reach and value-added services.
SWOT Analysis
Strengths: Effective treatment for rare diseases. Established brands with proven safety records.
Weaknesses: High development costs. Stringent regulatory norms. Dependence on plasma collection agencies.
Opportunities: Expanding into emerging markets. Developing subcutaneous and long-acting formulations.
Threats: Price controls and reimbursement hurdles. Rising frequency of patent expiries. Generics competition.
Key Takeaways
The Global Plasma Protease C1-inhibitor Treatment Market Growth is expected to witness high over the forecast period driven by rising incidence of hereditary angioedema, developing healthcare infrastructure, and new product innovations. The global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024-2031.
Regional analysis: North America currently dominates the market owing to large patient populations, favorable reimbursement policies, and presence of major players. However, Asia Pacific is estimated to grow at the fastest pace during the forecast period with increasing healthcare spending and expanding generics markets in China, India, and other developing countries.
Key players: Key players operating in the plasma protease C1-inhibitor treatment market are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. These leading manufacturers focus on collaborations with plasma collectors as well as partnerships with regional drug distributors to strengthen their presence across global markets.
Explore more information on this topic, Please visit -
https://www.ukwebwire.com/plasma-protease-c1-inhibitor-treatment-market-size-and-trends-analysis/
Explore more trending article related this topic -
https://www.rapidwebwire.com/the-largest-segment-driving-the-growth-of-anti-drone-market/
Comments
Post a Comment